Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer

BJU International

Volumn 110, Issue 11 B, 2012, Pages

  Heck, Matthias M ^a   Thalgott, Mark ^a   Retz, Margitta ^a   Wolf, Petra ^a   Maurer, Tobias ^a   Nawroth, Roman ^a   Hatzichristodoulou, Georgios ^a   Gschwend, Jürgen E ^a   Kübler, Hubert ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Castration resistant prostate cancer; Chemotherapy; Docetaxel rechallenge

Indexed keywords

DOCETAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; RADIOSENSITIZING AGENT; TAXOID;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG RECHALLENGE; HUMAN; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADENOCARCINOMA; BLOOD; COMPARATIVE STUDY; DISEASE COURSE; DOSE RESPONSE; FOLLOW UP; METASTASIS; MIDDLE AGED; ORCHIECTOMY; PROSTATE TUMOR;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84876448717     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11364.x     Document Type: Article

References (16)

1. Petrylak DP, Tangen CM, Hussain MHA et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 ; 351 : 1513-20
2. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 ; 351 : 1502-12
3. Berthold DR, Pond GR, Roessner M et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008 ; 14 : 2763-7
4. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008 ; 26 : 242-5
5. Mountzios I, Bournakis E, Efstathiou E et al. Intermittent docetaxel chemotherapy in patients with castrateresistant prostate cancer. Urology 2011 ; 77 : 682-7
6. Di Lorenzo G, Buonerba C, Faiella A et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int 2011 ; 107 : 234-9
7. Eymard J-C, Oudard S, Gravis G et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 2010 ; 106 : 974-8
8. Loriot Y, Massard C, Gross-Goupil M et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer 2010 ; 46 : 1770-2
9. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Intermittent chemotherapy in metastatic androgenindependent prostate cancer. Br J Cancer 2003 ; 89 : 968-70
10. Schallier D, Decoster L, Braeckman J, Fontaine C, Degrève J. Docetaxel in the Treatment of Metastatic Castrationresistant Prostate Cancer (mCRPC): an Observational Study in a Single Institution. A nticancer Res 2012 ; 32 : 633-41
11. Caffo O, Pappagallo G, Brugnara S et al. Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors. Urology 2012 ; 79 : 644-9
12. Oudard S, Kramer G, Creppy L et al. Management of metastatic castrationresistant prostate cancer (mCRPC) After an initial good response to first-line docetaxel (D) - a retrospective study on 270 patients (pts). Eur J Cancer 2011 ; 47 ( Suppl. 1 ): S499 - S500. 7049 [ abstract ]
13. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008 ; 1 : 1148-59
14. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011 ; 26 : 1995-2005
15. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010 ; 376 : 1147-54
16. Lin AM, Ryan CJ, Small EJ. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol 2007 ; 61 : 243-54